Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines--a phase II multipractice study.

BMC Cancer
Matthias JohnFAKT Study Group

Abstract

The 3-weekly combination of trastuzumab and paclitaxel has been approved for the treatment of advanced breast cancer based on a large pivotal study. However, mono and combination chemotherapy trials suggest that weekly paclitaxel has a better therapeutic index, especially in the palliative setting. The present trial examined the efficacy and safety of weekly paclitaxel over a limited duration combined with continued trastuzumab in HER2+ patients. Patients with histologically confirmed metastatic breast cancer overexpressing HER2 were eligible if pretreated with anthracycline in either the adjuvant or palliative setting. Treatment consisted of weekly trastuzumab (2 mg/kg/week for up to one year after a loading dose of 4 mg/kg in week 1) and paclitaxel (90 mg/m², administered in weeks 1-6 and 8-13). Twenty-seven German centers enrolled 121 patients. The median number of metastatic sites was two (range 1-5); 38% of patients had received chemotherapy for advanced disease. After a median 42 weeks of trastuzumab treatment, limited by disease progression in roughly half the patients, a best objective response rate (complete response + partial response) of 76% was achieved, including complete remissions in 29%. 74% of patients lived wi...Continue Reading

References

Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BaselgaL Norton
Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A D SeidmanL Norton
May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A D SeidmanC A Hudis
Nov 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E A PerezR Patel
Feb 2, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G FountzilasD Skarlos
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew SeidmanDeborah Keefe
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard BurrisJohn Hainsworth
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicholas RobertDennis Slamon
Jul 6, 2007·The New England Journal of Medicine·Clifford A Hudis
Apr 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alessandra GennariPaolo Bruzzi

❮ Previous
Next ❯

Citations

Jul 12, 2014·BioMed Research International·Mohamed HassanNoriaki Sakuragi
Dec 10, 2014·BMC Cancer·Christian JackischAxel Hinke
Jun 25, 2014·Hospital Pharmacy·Thomas LehmannJ Aubrey Waddell
Nov 21, 2020·Expert Review of Pharmacoeconomics & Outcomes Research·Vakaramoko DiabyAskal Ali

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.